JavaScript is disabled in your browser. You can still read and search, but features like search previews, menus, and forms may not work until it's enabled.

COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression

January 1, 2021 via Semantic Scholar

Relevant Not relevant

Abstract

No abstract available from the source.

Tags

Medicine Psychology

Psilocybin's effects on obsessive-compulsive behaviors: A systematic review of preclinical and clinical evidence Psychedelics. • October 28, 2025 • via OpenAlex
Therapeutic potential of psilocybin in the pharmacological treatment of obsessive-compulsive disorder: a scoping review protocol. Open Science Framework • July 9, 2026 • via OpenAlex
Sex-specific outcomes of developmental stress and psilocybin intervention on the brain and behavior Universitätsbibliothek der LMU • July 9, 2026 • via OpenAlex
Treating addiction with an addictive drug: the ketamine paradox revisited Frontiers in Psychiatry • July 9, 2026 • via OpenAlex
Beyond symptom reduction: DMT improves anxiety, life satisfaction, and quality of life in healthy volunteers and patients with depression Journal of Psychopharmacology • July 8, 2026 • via OpenAlex

Comments

No comments yet.

Log in to comment

Abstract

Tags

Related reading

Comments